Miraculins Inc.

Miraculins Inc.

February 01, 2007 09:01 ET

Miraculins Announces Appointment of Christopher J. Moreau as President and CEO

Dr. Jim Charlton to join the Company's board of directors

WINNIPEG, MANITOBA--(CCNMatthews - Feb. 1, 2007) - Miraculins Inc. (TSX VENTURE:MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products is pleased to announce that Mr. Christopher J. Moreau has been appointed president and chief executive officer.

Dr. Jim Charlton, who was appointed president of Miraculins in June 2004, will step down as president but will continue to provide guidance and leadership to the Company as a member of its board of directors effective February 1, 2007.

"I am delighted that Mr. Moreau has accepted the offer to head Miraculins as president and CEO", said Dr. Charlton. "His experience and leadership qualities make him the ideal individual to lead the Company through its next stages of development."

"I am pleased to announce Mr. Moreau's appointment as president and chief executive officer, commented Dr. Albert Friesen, chairman of Miraculins' board of directors, "Chris' unique blend of personal and professional skills will be fundamental in achieving the Company's key strategic goals going forward. I would like to thank Dr. Jim Charlton for the exceptional leadership he provided during his tenure as president; I look forward to working with him on the board of directors."

Previous to his appointment as president, Mr. Moreau served as Miraculins' vice president of business development since joining the Company in March, 2006. Mr. Moreau brings over 20 years experience in the areas of business development, sales, marketing and operations management. He has held several senior executive roles in sales and marketing within the telecommunications and manufacturing sectors. Prior to joining Miraculins, Mr. Moreau was the president of Advansis Capital Corporation, a privately held Canadian financial services provider.

"Miraculins has an exciting future as an emerging Canadian biotechnology company and I am pleased to assume the role of president and chief executive officer of a company with such potential", stated Mr. Moreau. "Having lost my father a number of years ago to Non Hodgkin's Lymphoma, cancer has touched me personally, and I am determined not to let his memory fade. Joining the Miraculins team has given me the opportunity to directly join the fight against cancer and keep the story of my father's fight alive. I am fortunate to have a solid scientific team and experienced management that show strong commitment and dedication to achieving success. I look forward to moving the Company towards the commercialization of its products."

As a component of his compensation package, Mr. Moreau has been granted 130,000 stock options by Miraculins' board of directors, pursuant to the Company's stock option plan. The options have an exercise price of $0.53 and are set to expire five years from the date of grant. The options are subject to regulatory approval.

About Miraculins Inc.

Miraculins is discovering, validating and developing biological markers (biomarkers) with clinical relevance for the diagnosis and treatment of cancers with critical unmet needs. The importance of tumor biomarkers for "common" cancers has been widely recognized and acknowledged by cancer experts and leading groups such as the National Cancer Institute and the American Cancer Society. The Company's BEST™ Platform utilizes the concurrent analysis of clinical factors and biological data, and a combination of proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery.

Certain information contained in this press release may be forward-looking statements and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information